Monitor for BiPASS top-line data readout and NDA submission timeline. The FDA alignment de-risks the regulatory pathway, but approval is not guaranteed. If positive, this could transform Telix's imaging franchise by moving PSMA-PET into the initial diagnostic setting, expanding the patient pool well beyond current staging/recurrence indications.
Drug in focus
TLX drug pipeline →Gozellix
▲ Bullish Named in this press release- Impact
- Phase
- Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- Time to market
- Already marketed — FDA approved March 21, 2025; US commercial launch announced June 2025
- Next catalyst
- None dated
What to watchGozellix is an already-approved, launched product, so there is no approval binary left to trade, the investor angle is commercial execution. Watch Telix's quarterly revenue disclosures (FY2026 guidance of ~US$950-970M plus US$40M Regeneron other income, Q2 2026 reported Aug 20, 2026) and any market-share data vs. Lantheus' PYLARIFY and Telix's own Illuccix, since Gozellix partly cannibalizes its sibling product. Bigger single-stock moves in TLX over the next year are more likely to come from the therapy pipeline (ProstACT Phase 3) than from this imaging agent.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $11.45entry
- T+1 · 3mo ago +2.53%α +1.49% · $11.74
- T+5 · 2mo ago +3.93%α +4.89% · $11.90
- T+20 · 7w ago −4.19%α −3.86% · $10.97
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
How similar events traded
Executive Summary
Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prostate cancer imaging, and aligned with the FDA on an NDA pathway. If successful, this could expand PSMA-PET imaging to a substantially larger patient population (3M biopsies/year globally, up to 75% negative), representing a significant label expansion opportunity for Telix's commercial imaging franchise.
Key Facts
- Phase 3 BiPASS study completed enrollment of 350 patients in the U.S. and Australia
- FDA alignment on NDA pathway for pre-biopsy prostate cancer imaging indication
- Prior PRIMARY/PRIMARY2 studies showed 68Ga-PSMA-PET + MRI can reduce unnecessary biopsies by ~50%
- Globally >3M prostate biopsies/year; up to 75% are negative, representing a large addressable market expansion
- Illuccix and Gozellix are already FDA-approved for staging and recurrence imaging; pre-biopsy would be a new product with separate reimbursement
Financial Impact
No financial data provided; potential to significantly expand addressable patient population for Telix's commercial PSMA-PET imaging agents, but revenue impact contingent on BiPASS data and FDA approval
Risk Factors
- BiPASS may fail to meet primary endpoints (diagnostic accuracy vs. standard of care)
- FDA may require additional data or reject the NDA despite alignment
- Competition from other PSMA-PET agents and alternative diagnostic approaches
- Reimbursement hurdles for new pre-biopsy indication
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354739 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Viewing Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers